Metformin in Postmenopausal Women With Metabolic Syndrome (NCT01342744) | Clinical Trial Compass
UnknownPhase 4
Metformin in Postmenopausal Women With Metabolic Syndrome
Thailand40 participantsStarted 2011-04
Plain-language summary
The purpose of this study is to determine the effects of metformin on cardiovascular risk factors in postmenopausal women with metabolic syndrome.
Who can participate
Age range45 Years – 60 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Postmenopausal women aged 45-60 years with metabolic syndrome according to The American Heart Association and The National Heart, Lung, and Blood Institute
Exclusion Criteria:
* Previous cardiovascular diseases
* Contraindicated to metformin: serum creatinine \>1.4 mg/dL, liver disease, alcoholism, congestive heart failure, chronic hypoxic lung disease, prior history of lactic acidosis
* Previous administration of metformin, other hypoglycemic drugs, lipid-lowering drugs, sex steroids, antiplatelet drugs within 3 months before enrollment
* Fasting blood sugar ≥ 200 mg/dL or HbA1c \>8%
* Serum triglyceride ≥500 mg/dL
* Abnormal EKG